INTRODUCTION
Immunologic destruction of cancer dates back to the 18th century with the observation that certain infectious disease processes confer a beneficial therapeutic effect on malignancy. In the early 20th century, some cancer patients demonstrated complete tumor regression after recovering from erysipelas. Subsequently, Coley and coworkers [1] [2] [3] used endotoxin from heat-killed streptococci and Serratia marcescens as a vaccine to treat more than 300 patients. Overall response rates were 63% in patients with sarcoma and 52% in those with lymphoma, with durable responses (many life-long) seen in 52% and 38%, respectively. Allogeneic bone marrow transplantation (alloBMT) has turned out to be another potent form of immunotherapy. There is ample evidence that a graftversus-tumor (GVT) effect exists with donor lymphocyte infusion (DLI) in patients with chronic myelogenous leukemia (CML) and those with graft-versus-host disease (GVHD) [3] [4] [5] [6] .
A critical role of alloBMT is to administer immunoregulatory cells to eradicate residual malignancy and prevent recurrences. It was once thought that high-dose therapy was necessary to eradicate host marrow stem cells and open up niches (extravascular sites of marrow hematopoiesis) to allow cell expansion; however, various studies have demonstrated that successful engraftment can occur in both nontreated hosts [7] [8] [9] [10] [11] and minimally treated hosts [12] [13] [14] . The key factor is the infusion of high numbers of donor cells to compete with residual host marrow. Stewart et al. [14] found that host marrow eradication was unnecessary and that syngeneic marrow could be transplanted into nontreated or minimally treated (100 cGy) mice, resulting in the establishment of long-term, multilineage chimerism. A total body irradiation (TBI) dose of 100 cGy resulted in high levels of donor chimerism with a reduction in host stem cell function to only 8.6% of the baseline level, while preserving host hematopoiesis. Final chimerism is based primarily on stem cell competition in the syngeneic setting [15] . These initial studies led to cellular immune therapy trials in which preparative treatment was minimized and immunocompetent T cell numbers were maximized.
In previous work [16] , we infused T cell-replete HLA-matched peripheral blood (1 Â 10 8 CD3 1 cells/ kg) from nonmobilized donors into patients with refractory hematologic malignancies treated with 100 cGy of TBI. Nine of 11 patients achieved mixed or complete donor chimerism, and 5 (55%) developed significant acute GVHD (aGVHD), resulting in 1 death. Remarkably, 4 complete responses (CRs) occurred, 2 of which (lymphoma and relapsed acute myelogenous leukemia [AML]) were of long duration. In addition, several patients had a CR while achieving only transient chimerism. One patient who achieved 5% chimerism at week 11 after infusion remained disease-free for more than 10 years after transplantation [16] .
In the aforementioned study, many eligible patients were untreated because of the lack of an HLA-identical matched sibling donor. Approximately 95% of patients have HLA-haploidentical relatives, however. Conventional high-dose, HLA-haploidentical immunotherapy is limited by toxicity, especially GVHD, but may exert potent GVT effects with the infusion of immunocompetent T or natural killer (NK) cells because of the haplodisparity between donor and host [17] [18] [19] [20] [21] . aGVHD can be reduced by T cell depletion, but this also abrogates the GVT effect [22] [23] [24] [25] [26] [27] [28] and increases rejection and infections [29, 30] .
Conventional dogma holds that sustained chimerism/engraftment is necessary for prolonged responses; however, our previous study found a long-term response with transient chimerism, suggesting that it is not required for a therapeutic effect. In the present Phase I/II study, we determined recipient response rates with HLA-haploidentical donors while infusing varying numbers of granulocyte colony-stimulating factor (G-CSF)-primed cells. G-CSF was used to polarize the T cells to a Th2 phenotype, to minimize GVHD in the event of engraftment [31] [32] [33] . The risk of graft rejection was increased because of HLA disparity [34] .
MATERIALS AND METHODS
All patients were enrolled on a protocol approved by the Roger Williams Medical Center's Institutional Review Board and Radiation Safety Committee.
Disease and eligibility characteristics are outlined in Table 1 .
Cell Collection Protocol
Initially, as a safety procedure, the first 10 patients underwent autologous peripheral blood stem cell (PBSC) apheresis and cell storage before transplantation. This was performed in case we needed to eradicate the graft because of GVHD. It was later discontinued because of lack of GVHD and engraftment.
Related HLA-haploidentical donors were given G-CSF (16 mg/kg/day) for 5 days, after which they underwent leukapheresis. If the donors needed additional CD31 cells, they were given G-CSF (16 mg/kg) 1 hour before the second leukapheresis. Thirty donors (73%) underwent leukapheresis over 2 days, and 11 (27%) did so over 1 day.
Conditioning
Patients were treated with 100 cGy of TBI given by lateral opposing fields at a rate of 10 to 15 cGy/min using a linear accelerator (25 MV) . Variations in the absorbed dose were within \ 10% of the dose to the prescription point throughout the body, with exception of the superficial 2 mm and the lungs. Beam spoilers of low-density plastic were used to achieve a more homogeneous surface dose. The collimator opening and treatment distance was such that the patient was entirely within the treatment beam without extension into the penumbra region. Individual patient-specific compensators (bolus material) provided X-ray dose uniformity; no shielding was provided. TBI was administered in the morning, and the leukapheresis product was given 6 hours later.
Cell Administration
The entire leukapheresis product was used. The cellular components were identical to those obtained by standard leukapheresis. T cell and CD34
1 concentrations were obtained, with the volume of product administered depending on T cell dose level. The patients were divided into 5 cohorts based on dose level: 1 Â No response was seen in those patients who received cyclosporine. CsA therapy was discontinued 4 weeks after initiation, once the absence of chimerism was confirmed.
Chimerism Analysis
In the first 20 patients, blood chimerism analysis done 2 weeks after transplantation revealed no detectable chimerism as determined by short-tandem repeats [16] . Because no chimerism was detected initially, we performed evaluations at earlier time points, including 1, 2, 3, 6, 14, and 21 days (in addition to the foregoing time points) after initial cell infusion, to explore the kinetics of rejection. We concomitantly evaluated serial marrow chimerism in a subset of patients with AML. The reproducible level of sensitivity in our assay, as monitored by control mixture lanes, was 1% to 5%. Percent donor engraftment or chimerism was defined as the percentage of total cells derived from donor DNA.
Haploimmunostorm Cytokine Analysis
The serum samples were stored in a freezer at 280 C until multiplex cytokine analysis was conducted using the Human 17-Plex Panel Cytokine Assay and the Bio-Plex Suspension Array System (Bio-Rad) according to the manufacturer's instructions.
Statistical Analysis
Primary endpoints included Phase I toxicity and Phase II response rates. Secondary a priori endpoints included response duration, chimerism, and toxicity. We expected accrual of 25 patients for the Phase II component. Sample size calculation was based on the primary endpoint of response rate. The null hypothesis was a response rate (CR 1 partial response [PR]) \ 1% versus the alternative hypothesis with a response rate $ 10%. With 25 patients, the study had 80% power with a 2-sided significance level of .05 to detect this difference. (All P values were 2-sided.) Objective measurements included restaging tests conducted beginning 30 days before therapy and continuing through day 100 after therapy. Disease (hematologic malignancy vs solid tumor), T cell dose, GVHD development, previous chemotherapy, neutropenia, and number of platelet/red blood cell (RBC) transfusions were studied as predictive factors for donor chimerism, tumor response, and toxicity. The nonparametric Spearman's rank correlation coefficient was used to assess the correlation between CD3 1 dose and survival by diagnosis (hematologic vs solid tumor). All statistical analyses were done using Stata 6.0 (StataCorp, College Station, TX).
Role of the Funding Source
The study sponsors had no role in study design, data collection, data analysis or interpretation, the writing of this manuscript, or the decision to submit the manuscript for publication.
RESULTS

Patient Characteristics
A total of 41 patients with refractory malignancies were enrolled into this Phase I/II protocol between June 2001 and March 2005. Median patient age was 58 years (range: 16 to 82 years). Human Research Review Committee approval was obtained before patients were enrolled. Disease distribution among the patients is outlined in Table 1 , and previous chemotherapy is described in Appendices 1 and 2. Six patients had previous autologous BMT, including 2 with breast cancer (5 months and 18 months earlier), 2 with lymphoma (8 months and 6 years earlier), 1 with myeloma (3 years earlier), and 1 with Ewing's sarcoma (4 months earlier). The median interval between autologous BMT and haplotransplantation was 25 months (range, 4 to 75 months), the median time from diagnosis to haplotransplantation was 21 months (range, 2 to 111 months), and the median number of previous treatment regimens was 3 (range, 0 to 7).
Median donor age was 41 years (range, 20 to 88 years). The group comprised 22 men and 19 women. A total of 17 donor-recipient pairs were sexmismatched, and 1 patient who died of presumed GVHD was sex-mismatched. Toxicity Figure 1A shows blood count changes in the patients with hematologic malignancies. During the first 8 weeks, the patients had an absolute neutrophil count (ANC)\1000 lasting a median of 37 days (range, 10 to 64 days) and an ANC\500 lasting a median of 27 days (range, 23 to 50 days). The mean ANC nadir was 340 on day 134. A bimodal mean distribution of the white blood cell (WBC) count and ANC was noted, with an initial drop by day 115, improvement by day 121, and then a second drop by day 134. The patients with solid tumors generally had a WBC count (median, 7.5 k/mL) and ANC (median: 5562) within normal ranges before treatment. The mean ANC never dropped below 500, with a nadir of 893 at day 132. Hemoglobin and hematocrit levels remained stable with blood transfusion support. Other toxicities are shown in Figure 1B .
In the 26 patients with hematologic malignancies dependency on blood products increased from 1 to 2 months before BMT to after BMT. RBC transfusion dependence increased from 80% (21 of 26) to 89% (23 of 26), and platelet dependence increased from 89% (23 of 26) to 92% (24 of 26). Seventeen of the 26 patients became transfusion-independent by day 100 after BMT.
Infusion-Related Syndrome
An acute clinical syndrome known as a ''haplo immunostorm'' (HIS) was observed after haplotransplantation, likely occurring secondary to cytokine flux. HIS represents neither hyperacute nor aGVHD, but rather is a syndrome comprising 1 or more symptoms, as outlined in Table 2 . Examples of the skin rash and biopsy findings in HIS are shown in Figure 2 , and serial serum multiplex cytokine level measurements are depicted in Figure 3 . In the 2 Â 10 8 CD3 1 cell/kg cohort (n 5 17), significant elevations (P \ .05) between pretransplantion and posttransfusion levels were found in interleukin (IL)-6, IL-8, IL-10, interferon (IFN)-g, IL-5, IL-7, IL-13, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1b. No significant changes were seen in IL-2, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF), INF-a, IL-1b, IL-7, IL-12, IL-17, or granulocyte colony-stimulating factor (G-CSF). This cytokine profile is unlike any reported previously and is separate from GVHD and engraftment syndrome.
Chimerism and aGVHD
The presence of chimerism was initially assessed at 2-week intervals, but because no evidence was found, we examined earlier time points after cell infusion. In most of the patients in the highest CD3 1 dose cohort (2 Â10 8 /kg CD3 1 ), transient donor chimerism was seen in the blood or marrow, but disappeared by 14 days; . 5% chimerism was observed in 10 of 29 patients given cells (Table 3) . Two patients converted to full donor chimerism (100%) by 24 and 28 days after cell infusion; one of these patients had active lymphoma, but developed severe aGVHD that was responsive to corticosteroids and died from polymicrobial sepsis, and the other died from disease progression (metastatic breast cancer) as noted on autopsy. This latter patient had undergone autologous BMT 18 months earlier, after which she developed mixed chimerism of 12.5% at 2 weeks and full chimerism (100%) at 24 days. She died 24 days after undergoing haplotransplantation from progressive disease with biopsy results negative for aGVHD.
The 8 patients treated with 1 Â 10 6 or 1 Â 10 7
CD3
1 cells/kg demonstrated no response. One patient with metastatic breast cancer treated with 1 Â10
1 cells/kg had stable disease without therapy for 7 months before progression was noted.
Of the 31 patients who received higher CD3 1 doses, objective responses were seen in 14 patients with hematologic malignancies (5 CR, 2 PR, and 7 transient response), and stable disease was seen in 1 patient with renal cell cancer. Three patients could not be evaluated because they died of other causes within a month of transplantation. Twenty-three patients exhibited disease progression, including 13 of 15 patients with solid tumor malignancies and 10 of 26 patients with hematologic malignancies. Interestingly, all of the responses were seen in the leukemia and lymphoma subgroup, and no responses were seen in the multiple myeloma (MM) subgroup. Four of 6 patients with relapsed, refractory B cell non-Hodgkin lymphoma (NHL) had a response (2 PR and 2 CR). The 2 patients with a CR had diffuse large cell lymphoma (DLCL) and lymphoblastic lymphoma, respectively, and were 76 and 82 months out of treatment, respectively, at the time of this writing. Serial computed tomography (CT) scans from the patient with DLCL showed a large volume abdominal tumor burden that continued to shrink despite lack of detectable chimerism or any further therapy ( Figure 4A ). Both patients with PR underwent subsequent autologous BMT, 1 at 112 days and the other at 380 days from haplotransplantation. The first patient, who had DLCL, had previously stored marrow cells and underwent transplantation because of persistent pancytopenia and residual disease. This patient converted to CR after autologous BMT, with a return to normal counts. The patient succumbed to cytomegalovirus (CMV) pneumonia 10 months later, but was free of lymphoma. The second patient, who had transformed follicular lymphoma (FL), had significant cardiomyopathy at the time of tumor recurrence, which prohibited autologous transplantation. This patient had a PR and underwent palliative therapy with rituximab and radiation to the main tumor bed. Although tumor shrinkage occurred, active disease persisted. The patient's cardiac function normalized, and autologous transplantation converted her to CR. She succumbed to refractory Babesiosis infection 56 months after haplotransplantation, free of recurrent lymphoma. Encouraging responses were seen in several patients with refractory AML; 3 of 13 patients obtained durable CR lasting 8, 11, and 31 months, respectively. The first patient died free of disease (as documented 1 week before death) from preexisting arteriovenous malformation bleeding complications. In the second patient, who had an underlying myelodysplastic syndrome (MDS), the leukemic clone was eliminated but residual myelodysplasia remained. The MDS had clonal evolution with recurrent or new AML developing 11 months after haplotransplantation. The patient declined further treatment. The third patient had relapsed, refractory active promyelocytic leukemia with a new chromosomal abnormality of 1:12. He demonstrated CR for 31 months after haplotransplantation, after which the disease recurred. He was brought into CR with arsenic trioxide and, after a second haplotransplantation, was disease-free at 38 months after his last treatment. Transient responses, defined as persistent loss of peripheral blood blasts and/or .50% reduction in marrow blasts on restaging of bone marrow 2 weeks after transplantation, were seen in 7 of 12 evaluable patients. These responses lasted a median of 19 6 5 days. Three of these patients demonstrated improved blood counts, and 6 demonstrated improved performance status. All responses occurred at CD3 The results were compared against a standard curve derived from recombinant cytokine standards ranging from of 0.2 to 3200 pg/mL. Cytokine concentrations were calculated using Bio-Plex Manager software (Bio-Rad). The data are presented in pg/mL. Serial serum samples were obtained in 17 patients at the 2 Â 10 8 CD3 1 cell/kg level. Cytokine levels were evaluated immediately before any therapy and then after cell infusion in patients with HIS during fever spikes. Significant elevations (P \.05) in the 2 Â 10 8 CD3 1 cell/kg cohort (n 5 17) between preinfusion and postinfusion values were seen in IL-6 (264 6 61 vs 3757 6 1308 pg/mL), IL-8 (21 6 7 vs 77 6 18 pg/mL), IL-10 (5 6 1.7 vs 91618.6 pg/mL), IFN-g (3.7 6 3.0 vs 30.9 6 6.4 pg/mL), IL-5 (1.28 6 0.49 vs 11.0 6 2.7 pg/mL), IL-7 (3.7 6 1.4 vs 7.7 6 1.1 pg/mL), IL-13 (0.51 6 0.28 vs 4.2 6 1.0 pg/mL), MCP-1 (87.1 6 25.4 vs 1188.7 6 773 pg/mL), and MIP-1b (94.9 6 18.5 vs 999. 8 marrow biopsy analyses performed in several patients showed evidence of large tumor reduction and early resumption of normal hematopoiesis ( Figure 4B ). Although the radiation therapy possibly could have elicited some transient antitumor response, our murine models demonstrated no change in marrow cellularity 9 days after 200 cGy of TBI (data not shown). (We used 200 cGy instead of 100 cGY, because the LD50 in mice is approximately double that in humans.) Figure 3C illustrates the kinetics of graft rejection. Except for the 2 patients who engrafted, no patients exhibited detectable chimerism by 3 weeks after haplotransplantation.
DISCUSSION
Nonengrafting haploidentical transplantation with minimal myeloablation (100 cGy) is an appropriate therapeutic strategy for older patients with significant comorbidities, and it provides a virtually universal donor pool. Side effects include well-tolerated myelotoxicity and an immediate postransplantation steroid-responsive immunologic syndrome. Significant antitumor responses, some complete and long-lasting, were seen in patients with leukemias and lymphomas in the absence of stable chimerism. Tumor responses occurred both early and late after haplotransplantation, with the most pronounced immediate antitumor responses seen in the patients with leukemias. The patients with lymphomas tended to experience continued tumor regression, as demonstrated in a patient with bulky disease that regressed slowly over 2 years. One patient with relapsed, refractory acute promyelocytic leukemia had gross marrow disease that disappeared 1 month after transplantation but was still polymerase chain reaction (PCR)-positive for PML-RARA protein (resolution of 1:100,000), becoming negative only after 2 months.
HIS likely is mediated by a cytokine storm that is exquisitely responsive to steroids. In the present study, it occurred only in patients who received at least 10 8 CD3 1 cells/kg. The associated cytokines differ from those implicated in GVHD or engraftment syndrome, which include IL-1, IL-2, IL-8, TNF-a, and IFN-g. HIS also differs from engraftment syndrome in terms of negative skin and intestinal biopsy results and the absence of noncardiogenic edema, renal insufficiency, weight gain, and encephalopathy. HIS may be critical to our observed tumor responses. The increased presence of MCP-1 and MIB-1b, which up-regulate NK cell function and recruitment, suggests that NK cells play a role in this syndrome, possibly in mediating tumor response [34] . Although GVT and GVHD are closely associated, animal models have shown evidence that antitumor activity can be seen with minimal or no obvious GVHD [19, 35, 36] . Evidence also exists suggesting that GVT and GVHD may be separable in alloBMT [37, 38] . In the present study tumor responses were seen with no evidence of GVHD. This finding is consistent with failure of engraftment or graft rejection. Dey et al. [39] reported antitumor responses with chimerism loss in 9 of 22 patients after nonmyeloablative conditioning and alloBMT. Seven of 9 patients who lost chimerism were alive at 2.5 to 5.5 years after transplantation. In this setting, however, there was initial engraftment, and an initial T cell-mediated GVT reaction was possible, because T cell chimerism was present at 2 weeks posttransplantation (. 5%) in 8 of 9 patients. The authors favored the hypothesis that a host-versus-graft response with associated rejection promoted the antitumor responses. We favor a similar hypothesis for the tumor responses noted in our patients, who never obtained chimerism, although the 2 trials had major differences. In our study, no responding patient demonstrated chimerism past 2 weeks posttransplantation, whereas the patients of Dey et al. [39] had initial engraftment with chimerism persisting for 21 to 144 days. In our study, there was an immediate cytokine-related syndrome with both early and later responses. Although we cannot rule out the possibility of microchimerism (\ 5%) with a T cell attack against the tumor, our results demonstrating no evidence of engraftment or GVHD in responders, along with different cytokine elevations than are associated with classic GVHD/GVT suggest that this is not the case.
Alternatively, we cannot rule out the possibility that a graft-versus-host reaction, rather than a hostversus-graft reaction (ie, graft rejection), was responsible for awakening host-derived antitumor immunity. This type of response was suggested by Rajewsky et al. [40] characterized in a guinea pig model by Ellman and coworkers [41, 42] and later demonstrated in a murine model [43] .
We speculate that the cells responsible for the cytokine HIS, which may be related to donor cell rejection, altered the host's tolerance to the tumor and allowed for a host immune response against the tumor. This theory is further supported in murine models showing that host antidonor immune responses causing spontaneous or intentionally induced graft rejection by recipient lymphocyte infusions produced antitumor responses against recipient tumors [44] . In addition, host antidonor responses capable of eliminating allogeneic donor WBCs have been shown to be potent and rapidly activated, producing almost complete (99.9%) elimination of donor cells within 3 days after transfusion [45] . Rapid elimination of large volumes of allogeneic donor splenocytes was found to be mediated by recipient CD8
1 cells stimulated by donor CD4 1 T cells. Alloantibodies seem to be responsible for the elimination of allogeneic donor cells in the absence of recipient CD8 1 cells. There is evidence that the potent host antidonor response could attack tumors, because of the cross-reactive nature of alloreactivity [46] [47] [48] . Administering G-CSF before donor collection potentially enhanced the antigenpresenting capabilities of the donor WBC's and thereby increased the host antidonor responses, thus increasing the antitumor response. The early transient responses may well have resulted from lysis of tumor cells by the infused T cells or NK cells; this probably does not explain the longer-term responses, however [49, 50] . Other cell types, such as T regulatory cells, may have played a role in modulating or enhancing the responses. The present trial was not initially designed to separate out this type of information. Giving addition infusions at 6-to 8-week intervals would be of interest to evaluate those patients with transient responses or large tumor burdens.
In summary, our findings indicate that TBI of 100 cGy followed by HLA-haploidentical transplantation is a biologically active therapy for refractory hematologic disease. The patients with AML and lymphomas had a high response rate, even when taking into account that many of the patients treated with this protocol were enrolled in the Phase I component of this trial. These data further suggest that persistent donor chimerism may not be necessary for durable antitumor response. The rejection of donor-derived cells in concert with elevated levels of specific cytokines may represent a novel therapeutic approach for hematologic malignancies.
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